Pharming Group NV (PHAR): Price and Financial Metrics

Pharming Group NV (PHAR): $7.94

-0.09 (-1.12%)

POWR Rating

Component Grades













Add PHAR to Watchlist
Sign Up

Industry: Biotech


of 481

in industry


  • PHAR scores best on the Growth dimension, with a Growth rank ahead of 0% of US stocks.
  • PHAR's strongest trending metric is Growth; it's been moving down over the last 28 days.
  • PHAR's current lowest rank is in the Growth metric (where it is better than 0% of US stocks).

PHAR Stock Summary

  • With a one year PEG ratio of 4.36, Pharming Group NV is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than just 15.13% of US stocks.
  • PHAR's went public 0.94 years ago, making it older than just 0.38% of listed US stocks we're tracking.
  • With a year-over-year growth in debt of 68.98%, Pharming Group NV's debt growth rate surpasses 88.2% of about US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Pharming Group NV are SRGA, TDW, UAMY, POAI, and LIVN.
  • To check out Pharming Group NV's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001828316.

PHAR Stock Price Chart Interactive Chart >

Price chart for PHAR

PHAR Price/Volume Stats

Current price $7.94 52-week high $21.99
Prev. close $8.03 52-week low $7.94
Day low $7.94 Volume 1,458
Day high $8.12 Avg. volume 6,359
50-day MA $9.26 Dividend yield N/A
200-day MA $11.72 Market Cap 513.58M

Pharming Group NV (PHAR) Company Bio

Pharming Group NV is a biopharmaceutical company involved with the development, production and commercialization of human therapeutic proteins to be used in highly innovative therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage, and surgical/traumatic bleeding.

PHAR Latest News Stream

Event/Time News Detail
Loading, please wait...

PHAR Latest Social Stream

Loading social stream, please wait...

View Full PHAR Social Stream

Latest PHAR News From Around the Web

Below are the latest news stories about Pharming Group NV that investors may wish to consider to help them evaluate PHAR as an investment opportunity.

Buy These 2 Stocks Before They Jump Over 100%, Says Oppenheimer

What happens when headwinds meet tailwinds? In meteorology, head-on collisions of opposite air masses gives birth to thunderstorms; add some Coriolis force, and the storm becomes cyclonic. As historian Bruce Catton once described such action, in a political context, ‘tornado weather: sultriest and most menacing.’ But it seems, for now, that we’ve missed that bullet. As Oppenheimer’s chief investment strategist John Stoltzfus writes, “While economic data continues to show persistently high levels of inflation attributable to supply chain shocks as well as labor shortages, more people are returning to work and demand for services has increased.

Michael Marcus on TipRanks | November 2, 2021

Pharming Group (NASDAQ:PHAR) Reaches New 12-Month Low at $8.25

Pharming Group (NASDAQ:PHAR) reached a new 52-week low during trading on Thursday . The stock traded as low as $8.25 and last traded at $8.25, with a volume of 24 shares trading hands. The stock had previously closed at $9.61. Separately, Zacks Investment Research raised shares of Pharming Group from a sell rating to a []

Dakota Financial News | October 28, 2021

Pharming Group N.V.: Pharming Group reports financial results for the first nine months of 2021

Patient enrollment and product demand driving ongoing revenue recovery to US$52.9 million in Q3 2021 Operating profit impacted by upfront payment of US$ 13.1 million for the in-licensing of OTL-10

FinanzNachrichten | October 28, 2021

Pharming Group NV (PHGUF) to Report Q3 Results: What Awaits?

Pharming Group NV (PHGUF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | October 28, 2021

Pharming Group reports financial results for the first nine months of 2021

Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM/NASDAQ: PHAR) presents its preliminary (unaudited) financial report for the first nine months ended September 30, 2021.

Yahoo | October 28, 2021

Read More 'PHAR' Stories Here

PHAR Price Returns

1-mo -11.78%
3-mo N/A
6-mo -35.02%
1-year N/A
3-year N/A
5-year N/A
YTD -47.75%
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7182 seconds.